BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31813661)

  • 21. IMRT improves local control in patients with nasopharyngeal carcinoma compared with conventional radiotherapy: propensity score-matched analysis.
    Ma Z; Umezawa R; Yamamoto T; Ishikawa Y; Takahashi N; Takeda K; Suzuki Y; Tang L; Ito K; Kadoya N; Jingu K
    Jpn J Clin Oncol; 2021 Aug; 51(9):1444-1451. PubMed ID: 34250545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-Dose Static and Dynamic Intensity-Modulated Radiotherapy Combined with Chemotherapy for Patients with Locally Advanced Nasopharyngeal Carcinoma Improves Survival and Reduces Brainstem Toxicity.
    Sun PY; Chen YH; Feng XB; Yang CX; Wu F; Wang RS
    Med Sci Monit; 2018 Dec; 24():8849-8859. PubMed ID: 30524119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor Regression and Patterns of Distant Metastasis of T1-T2 Nasopharyngeal Carcinoma with Intensity-Modulated Radiotherapy.
    Wu MY; He XY; Hu CS
    PLoS One; 2016; 11(4):e0154501. PubMed ID: 27119991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Outcome and Prognostic Factors of Intensity-Modulated Radiotherapy for T4 Stage Nasopharyngeal Carcinoma.
    Luo Y; Gao Y; Yang G; Lang J
    Biomed Res Int; 2016; 2016():4398498. PubMed ID: 27195286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stage-dependent conditional survival and failure hazard of non-metastatic nasopharyngeal carcinoma after intensity-modulated radiation therapy: Clinical implications for treatment strategies and surveillance.
    Wang J; Huang X; Sun S; Wang K; Qu Y; Chen X; Wu R; Zhang Y; Liu Q; Zhang J; Luo J; Xiao J; Gao L; Xu G; Hu C; Li YX; Yi J
    Cancer Med; 2021 Jun; 10(11):3613-3621. PubMed ID: 33960136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
    Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update report of T4 classification nasopharyngeal carcinoma after intensity-modulated radiotherapy: an analysis of survival and treatment toxicities.
    Cao CN; Luo JW; Gao L; Yi JL; Huang XD; Wang K; Zhang SP; Qu Y; Li SY; Xiao JP; Zhang Z; Xu GZ
    Oral Oncol; 2015 Feb; 51(2):190-4. PubMed ID: 25434585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma.
    Setton J; Han J; Kannarunimit D; Wuu YR; Rosenberg SA; DeSelm C; Wolden SL; Jillian Tsai C; McBride SM; Riaz N; Lee NY
    Oral Oncol; 2016 Feb; 53():67-73. PubMed ID: 26675283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advantages of using reduced-volume intensity modulated radiation therapy for the treatment of nasopharyngeal carcinoma: a retrospective paired study.
    Liu F; Luo T; Jin T; Zhang J; Xiang Z; Yan R; Xie L; Wu X; Zhang H; Wang F; Li P; Liu L
    BMC Cancer; 2019 Jun; 19(1):554. PubMed ID: 31176358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy.
    Han F; Zhao C; Huang SM; Lu LX; Huang Y; Deng XW; Mai WY; Teh BS; Butler EB; Lu TX
    Clin Oncol (R Coll Radiol); 2012 Oct; 24(8):569-76. PubMed ID: 22209574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk Assessment of Secondary Primary Malignancies in Nasopharyngeal Carcinoma: A Big-Data Intelligence Platform-Based Analysis of 6,377 Long-term Survivors from an Endemic Area Treated with Intensity-Modulated Radiation Therapy during 2003-2013.
    Zhang LL; Li GH; Li YY; Qi ZY; Lin AH; Sun Y
    Cancer Res Treat; 2019 Jul; 51(3):982-991. PubMed ID: 30309219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of induction chemotherapy combined with chrono-chemotherapy and intensity-modulated radiotherapy on locally advanced nasopharyngeal carcinoma.
    Zhang S; Liu TTGLYLQLWHY
    J BUON; 2021; 26(3):774-780. PubMed ID: 34268935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma.
    Ng WT; Lee MC; Hung WM; Choi CW; Lee KC; Chan OS; Lee AW
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):420-8. PubMed ID: 20452132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma.
    Chen L; Zhang Y; Lai SZ; Li WF; Hu WH; Sun R; Liu LZ; Zhang F; Peng H; Du XJ; Lin AH; Sun Y; Ma J
    Oncologist; 2019 Jan; 24(1):e38-e45. PubMed ID: 30082487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
    Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
    Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone.
    Su SF; Han F; Zhao C; Chen CY; Xiao WW; Li JX; Lu TX
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):327-33. PubMed ID: 21035959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
    Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C
    Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma.
    Lee VH; Kwong DL; Leung TW; Choi CW; Lai V; Ng L; Lam KO; Ng SC; Sze CK; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; Khong PL
    Oncotarget; 2017 Jan; 8(3):5292-5308. PubMed ID: 28029657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy: A meta-analysis.
    Leong YH; Soon YY; Lee KM; Wong LC; Tham IWK; Ho FCH
    Head Neck; 2018 Mar; 40(3):622-631. PubMed ID: 29130584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.